%PDF-1.4
%
74 0 obj
<>
endobj
71 0 obj
<>
endobj
136 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-21T18:22:57Z
2024-03-28T01:39:52-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T01:39:52-07:00
application/pdf
Heather
200434 sept
uuid:b90eb672-1dd1-11b2-0a00-9208276d7200
uuid:b90eb675-1dd1-11b2-0a00-b80000000000
endstream
endobj
60 0 obj
<>
endobj
61 0 obj
<>
endobj
75 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 42 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 44 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 46 0 R/Type/Page>>
endobj
12 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 48 0 R/Type/Page>>
endobj
30 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 50 0 R/Type/Page>>
endobj
33 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 52 0 R/Type/Page>>
endobj
36 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 54 0 R/Type/Page>>
endobj
162 0 obj
[166 0 R]
endobj
163 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
0 0 0 0 k
/GS1 gs
465 777 92 -27 re
f*
0 0 0 1 K
54 54 m
558 54 l
S
BT
0 0 0 1 k
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2001; 28:9)Tj
0 Tc 0 Tw -46.2952 -0.0313 Td
(1966)Tj
ET
0 0 0 0 k
/GS0 gs
103.72 58.75 407.5 -10.83 re
f*
0.5 w
103.72 58.75 407.5 -10.83 re
S
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 74.4 714.5293 Tm
(arthritis. Scand J Rheumatol 1988;17:203-12.)Tj
-2.175 -1.25 Td
[(30.)-875.1 (Malaise MG, Franchimont P)110.7 (. Defective in vitro )]TJ
/T1_2 1 Tf
0 Tc 0 Tw 21.4328 0 Td
(\002)Tj
/T1_1 1 Tf
-0.0002 Tc [-0.1 (-interferon)]TJ
-0.00011 Tc 0.02499 Tw -19.2578 -1.25 Td
[(production in rheumatoid arthritis. )54.8 (Arthritis Rheum 1987;30:230-1.)]TJ
-2.175 -1.25 Td
[(31.)-875.1 (W)79.9 (akikawa )54.8 (A, Utsuyama M, )17.7 (W)79.9 (akabayashi )54.8 (A, Kitagawa M,)]TJ
2.175 -1.25 Td
[(Hirokawa K. )54.8 (Age-related alteration of cytokine production profile)]TJ
0 -1.25 TD
[(by )17.7 (T)-257.1 (cell subsets in mice: a flow cytometric study)64.8 (. Exp Gerontol)]TJ
0 Tc 0 Tw T*
(199;34:231-42.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(32.)-875.1 (Y)99.8 (oshii H, )36.8 (Y)99.8 (amamoto K, Okudaira H, et al. )54.8 (Age-related dif)17.7 (ferential)]TJ
2.175 -1.25 Td
[(mRNA)-220.2 (expression of )17.7 (T)-257.1 (cell cytokines in NZB/NZW)-257.3 (F1 mice.)]TJ
0 Tc T*
(Lupus 1995;4:213-6.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(33.)-875.1 (Karanfilov CI, Liu B, Fox CC, Lakshmanan RR, )17.7 (Whisler RL. )54.8 (Age-)]TJ
2.175 -1.25 Td
[(related defects in )17.7 (Th1 and )17.7 (Th2 cytokine production by human )17.7 (T)]TJ
T*
(cells can be dissociated from altered frequencies of CD45RA+ and)Tj
T*
[(CD45RO+ )17.7 (T)-257.1 (cell subsets. Mech )54.8 (Ageing Dev 1999;109:97-1)36.8 (12.)]TJ
-2.175 -1.25 Td
[(34.)-875.1 (Nijhuis EW)91.7 (, Remarque EJ, Hinloopen B, et al. )54.8 (Age-related increase)]TJ
2.175 -1.25 Td
[(in the fraction of CD27-CD4+ )17.7 (T)-257.1 (cells and IL-4 production as a)]TJ
T*
[(feature of CD4+ )17.7 (T)-257.1 (cell dif)17.7 (ferentiation in vivo. Clin Exp Immunol)]TJ
0 Tc 0 Tw T*
(1994;96:528-34.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(35.)-875.1 (Hobbs MV)128.8 (, )17.7 (W)79.9 (eigle )17.7 (WO, Ernst DN. Interleukin-10 production by)]TJ
2.175 -1.25 Td
(splenic CD4+ cells and cell subsets from young and old mice. Cell)Tj
T*
(Immunol 1994;154:264-72.)Tj
-2.175 -1.25 Td
[(36.)-875.1 (Castle S, Uyemura K, )17.7 (W)79.9 (ong )17.7 (W)91.8 (, Modlin R, Ef)17.7 (fros R. Evidence of)]TJ
2.175 -1.25 Td
(enhanced type 2 immune response and impaired upregulation of a)Tj
T*
(type 1 response in frail elderly nursing home residents. Mech)Tj
T*
(Ageing Dev 1997;94:7-16.)Tj
-2.175 -1.25 Td
[(37.)-875.1 (Thompson PW)91.7 (, Silman )54.8 (A, Kirwan JR, Currey HLF)79.7 (. )54.8 (Articular)]TJ
2.175 -1.25 Td
[(indices of joint inflammation in rheumatoid arthritis. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 1987;30:618-23.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(38.)-875.1 (V)110.8 (an der Heijde DM, van Riel PL, Nuver)19.7 (-Zwart IH, Gribnau FW)91.7 (,)]TJ
2.175 -1.25 Td
[(van de Putte LB. Ef)17.7 (fects of hydroxychloroquine and sulphasalazine)]TJ
T*
(on progression of joint damage in rheumatoid arthritis. Lancet)Tj
0 Tc 0 Tw T*
(1989;1:1036-8.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(39.)-875.1 (June CH, Bluestone JA, Nadler LM, )17.7 (Thompson LB. )17.7 (The B7 and)]TJ
2.175 -1.25 Td
[(CD 28 receptor families. Immunol )17.7 (T)69.9 (oday 1994;15:321-31.)]TJ
30.825 41.25 Td
[(40.)-875.1 (V)110.8 (an der Pouw-Kraan )17.7 (T)74 (,)-0.1 ( )17.7 (V)110.8 (a)-0.1 (n Kooten C, Rensink I, )54.8 (Aarden L.)]TJ
2.175 -1.25 Td
[(Interleukin-4 production by human )17.7 (T)-257.1 (cells. Eur J Immunol)]TJ
0 Tc 0 Tw T*
(1992;2:1237-41.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(41.)-875.1 (V)110.8 (erhoef CM, van Roon JAG, )17.7 (V)59.8 (ianen ME, Glaudemans CAFM,)]TJ
2.175 -1.25 Td
[(Lafeber FPJG, Bijlsma JWJ. L)54.8 (ymphocyte stimulation by CD3-)]TJ
T*
[(CD28 enables detection of low )17.7 (T)-257.1 (cell interferon-)]TJ
/T1_2 1 Tf
0 Tc 0 Tw [-0.4 (\002)]TJ
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 20.2888 0 Td
(and interleukin-4)Tj
-20.2889 -1.25 Td
(production in rheumatoid arthritis. Scand J Immunol )Tj
0 Tc 0 Tw T*
(1999;50:427-32.)Tj
-0.00011 Tc 0.0249 Tw -2.175 -1.25 Td
[(42.)-875.1 (Barrera P)110.7 (, Boerbooms )54.7 (AMT)73.9 (, Janssen EM, et al. Circulating soluble)]TJ
2.175 -1.25 Td
(tumor necrosis factor receptors, interleukin-2 receptors, tumor)Tj
T*
(necrosis factor )Tj
/T1_2 1 Tf
0 Tc 0 Tw [-0.1 (\003)]TJ
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw [0.1 (, and interleukin-6 levels in rheumatoid arthritis.)]TJ
0.0001 -1.25 Td
(Arthritis Rheum 1993;36:1070-8.)Tj
-2.175 -1.25 Td
[(43.)-875.1 (Barrera P)110.7 (, Haagsma CJ, Boerbooms )54.7 (AMTh, et al. Ef)17.7 (fect of)]TJ
2.175 -1.25 Td
(methotrexate alone or in combination with sulphasalazine on the)Tj
T*
(production and circulating concentrations of cytokines and their)Tj
T*
(antagonists. Br J Rheumatol 1995;34:747-55.)Tj
-2.175 -1.25 Td
[(44.)-875.1 (Rudwaleit M, )36.8 (Y)54.9 (in Z, Siegert S, et al. Response to methotrexate in)]TJ
2.175 -1.25 Td
[(early rheumatoid arthritis is associated with a decrease of )17.7 (T)-257.1 (cell)]TJ
T*
(derived tumour necrosis factor alpha, increase of interleukin 10,)Tj
T*
[(and predicted by the initial concentration of interleukin 4. )54.8 (Ann)]TJ
T*
[(Rheum Dis 2000;59:31)36.8 (1-4.)]TJ
-2.175 -1.25 Td
[(45.)-875.1 (Keijsers )17.7 (V)128.9 (,)-0.1 ( )17.7 (T)69.9 (ong )17.7 (TQT)73.9 (, )17.7 (V)110.8 (erweij CL, et al. Innate dif)17.7 (ferences in IL-)]TJ
2.175 -1.25 Td
(10 production are present at the level of transcription and)Tj
T*
(associated with haplotypes: association of IL-10 haplotypes and)Tj
T*
[(rheumatoid arthritis [abstract]. )54.8 (Arthritis Rheum 1998;41 Suppl:188.)]TJ
-2.175 -1.25 Td
[(46.)-875.1 (W)79.9 (estendorp RGJ, Langermans JAM, Huizinga )17.7 (TWJ, et al. Genetic)]TJ
2.175 -1.25 Td
(influence on cytokine production and fatal meningococcal disease.)Tj
T*
(Lancet 1997;349:170-3.)Tj
-2.175 -1.25 Td
[(47.)-875.1 (Schwartz M, Majdic O, Knapp )17.7 (W)91.8 (, Holter )17.7 (W)91.8 (. High-level IL-10)]TJ
2.175 -1.25 Td
[(production by monoclonal antibody-stimulated human )17.7 (T)-257.1 (cells.)]TJ
T*
(Immunol 1995;86:364-71.)Tj
-2.175 -1.25 Td
[(48.)-875.1 (Y)110.8 (udoh K, Matsuno H, Nakazawa F)79.7 (,)-0.1 ( )36.8 (Y)99.8 (onezawa )17.7 (T)74 (, Kimura )17.7 (T)74 (.)]TJ
2.175 -1.25 Td
[(Reduced expression of the regulatory CD4+ )17.7 (T)-257.1 (cell subset is related)]TJ
T*
[(to )17.7 (Th1/Th2 balance and disease severity in rheumatoid arthritis.)]TJ
T*
(Arthritis Rheum 2000;43:617-27.)Tj
ET
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_3 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2001. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
54 0 obj
<>stream
8;Z\7Mb_/T%*S\N@"*m9eW9@jBNHS`.7O`*VMX>+gb#k[phtu0a3Wf=oAtgTom&Q-
+.+c069lgr4E'hQ/KKFLH%oQC0pDhr-TE9]C64Cimr_u^!38DAmD>D"lOU:s;ZjA1
F!1E)Q__aqk`RH8nb)qH;4`lX*"LMgKV;:s26n7bfj_F@j`?p-U')eG;lWS?;o.9m
el#)sNQEVY8CL>WeM?RF#i.1-a0!0sKb^2\eZXL5Nf=_(PkJ[2#7^AY,e[aGNm4"n
A"6VA#5>#mH-A>&:SkD8Zb[_O=;gR5TRhn0k7Oel.$%hLpnrNA2j[O6A_NDmqm&_K
endstream
endobj
58 0 obj
[/Indexed/DeviceRGB 255 57 0 R]
endobj
57 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
77 0 obj
<>
endobj
81 0 obj
<>
endobj
82 0 obj
<>
endobj
121 0 obj
<>
endobj
141 0 obj
<>
endobj
83 0 obj
<>
endobj
86 0 obj
<>
endobj
85 0 obj
<>stream
HT=o w~ō:`],$&Uvl!ŀ0FOziV3CbV'VTg/{4$wqnhiŻ
6Z ;N _'n3jpGB/ス3pNMFb{BS0ZӞ1&)ʂPF;Iu"1ڧ eY#sPIW?_΅VqyUkl;>+ Сv
endstream
endobj
84 0 obj
<>stream
H\_LRq-bGp︤e1ݴ\=9nMDDÒ)
@ XJ|R̭ƃw'إy8=g{vP AQ#+H*Jڳ:MJ9@Y:ESEmm hD(%iT&`Qh}BmT)*Aj-&VB=$
[hB|FA!QDW7 ]8Lr $N,`pc",Prfb.Cez~ 5(X~_Tɱy~(l%JU^r$oR